EXPLANATORY STATEMENT
National Health Amendment (Immunisation Program) Act 2005 - Proclamation
National Health Act 1953
Proclamation
Subsection 2(1) of the National Health Act 1953 (the NHA) provides that Schedule 1 to the National Health Amendment (Immunisation Program) Act 2005 (the Act) commences on a day to be fixed by Proclamation. The NHA also provides that if any of the provisions of Schedule 1 do not commence within six months of the date the Act receives the Royal Assent, then those provisions commence on the first day after the end of that six month period. The Act received Royal Assent on 18 November 2005.
Part 1 of Schedule 1 to the Act repeals section 9B of the National Health Act 1953.
Section 9B empowered the Minister to provide, or arrange for the provision of, vaccine for the purpose of immunizing persons against poliomyelitis, mumps, measles, rubella, and any other disease prescribed in the National Health Regulations 1954 (the Principal Regulations). The Act also replaces the repealed section 9B with a new section 9B that gives the Minister the power to provide, or to arrange the provision of, designated vaccines and to determine by legislative instrument that a specified vaccine is a designated vaccine for the purposes of the National Health Act 1953.
Part 2 of Schedule 1 to the Act increases the size of the Pharmaceutical Benefits Advisory Committee (PBAC) from up to 15 members to up to 17 members and provides for the Chairperson of the PBAC to hold the office on a full time basis. Consistent with the Budget announcement for this policy the purpose of the Proclamation is to fix 1 January 2006 as the day on which Schedule 1 to the Act will commence.
Overview
The National Health Amendment (Immunisation Program) Act 2005, enacted in 2005, was introduced to address the need for an updated immunisation program within the existing legislative framework. This Act amends the National Health Act 1953 to modernise and streamline the processes related to immunisation. The enactment by the Parliament of Australia aimed to empower the Minister to efficiently provide or arrange for the provision of designated vaccines, ensuring a more targeted and effective immunisation program. The policy objective was to enhance the public health infrastructure by allowing for the timely and strategic introduction of vaccines against specified diseases, thus improving the overall health outcomes of the population. The Act also sought to increase the capacity of the Pharmaceutical Benefits Advisory Committee, enabling more comprehensive evaluations and recommendations on pharmaceutical benefits, including those related to vaccines.
Scope and Application
The National Health Amendment (Immunisation Program) Act 2005, as proclaimed under the National Health Act 1953, extends its application to the Minister of Health who is granted new powers to provide or arrange the provision of designated vaccines, a role previously defined under section 9B of the National Health Act 1953. This Act operates within the Commonwealth jurisdiction and its provisions, which include the replacement of the repealed section 9B with a new section 9B, will come into effect on 1 January 2006. Additionally, the Act modifies the Pharmaceutical Benefits Advisory Committee by increasing its size from up to 15 to up to 17 members, and stipulates that the Chairperson's role is now to be held on a full-time basis. The Act does not explicitly state any exclusions, exemptions, or thresholds, but the power to determine which vaccines are designated is delegated to the Minister through legislative instruments.
Key Provisions
The key provisions of the National Health Amendment (Immunisation Program) Act 2005, as proclaimed, primarily revolve around the amendments to the National Health Act 1953. The Act introduces significant changes to the framework for immunisation programs in Australia. Firstly, it repeals the existing section 9B of the National Health Act 1953 (section 1(1)) which previously empowered the Minister to provide or arrange for the provision of vaccines for specific diseases. This section is replaced with a new section 9B (section 1(2)) that expands the Minister's authority to provide or arrange for the provision of designated vaccines, allowing for more flexibility in immunisation programs. The Minister can now determine by legislative instrument which vaccines are designated, providing a more targeted approach to immunisation efforts.
The obligations imposed by the Act on the relevant parties include the Minister's responsibility to provide or arrange for the provision of designated vaccines as defined by legislative instruments. This ensures that immunisation programs are based on up-to-date and scientifically informed decisions. Furthermore, the Act mandates that the Pharmaceutical Benefits Advisory Committee (PBAC) is expanded from up to 15 members to up to 17 members (section 2(1)), enhancing the committee's capacity to review and advise on the inclusion of vaccines in the immunisation program. The Chairperson of the PBAC is also required to hold the office on a full-time basis (section 2(2)), reflecting the importance of this role in the decision-making process for immunisation.
Breaching the provisions of the Act can result in significant legal consequences. While the explanatory statement does not specify particular offences or penalties, the Act operates within the broader framework of the National Health Act 1953, which may include civil or criminal penalties for non-compliance. The maximum penalties for breaches could vary depending on the nature and severity of the offence, and are typically detailed in the primary legislation or relevant regulations. Given the critical public health implications of immunisation programs, any failure to comply with the Act's provisions could lead to serious repercussions, including fines, imprisonment, or both.